BioCardia Inc BCDA.OQ BCDA.O is expected to report resultson May 14 for the period ending March 31 2025
LSEG's mean analyst estimate for BioCardia Inc is for a loss of 39 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for BioCardia Inc is $15.50, above its last closing price of $2.85.
This summary was machine generated May 12 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)